Postpartum Low-Dose Aspirin and Preeclampsia

Preeclampsia Postpartum Clinical Trial

Official title:

Low-Dose Aspirin in the Postpartum Period and Endothelial Function in Patients With Preeclampsia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03667326
• Other study ID #: AAAR9439
• Status: Recruiting
• Phase: Phase 2
• Start date: July 22, 2019
• Est. completion date: December 2023

Study information

• Verified date: December 2022
• Source: Columbia University
• Contact: Aleha Aziz, MD, MPH
• Phone: 646-678-0289
• Email: aa4065[@]cumc.columbia.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.

Description:

Preeclampsia is a serious disease of pregnancy that manifests with increased blood pressure and can affect all the organs in a woman's body. It usually develops after 20 weeks of pregnancy. There is an abnormal amount of protein in the urine and with worsening disease known as "severe features," patients can have pain in the upper abdomen, changes in vision, fluid in the lungs, an intense headache, low number of platelets in the blood, and abnormal liver or kidney function. Very high blood pressure is also considered a severe feature. The exact cause of preeclampsia is unknown but women with the condition are at increased risk for complications during pregnancy, including seizures - eclampsia. Babies are at risk of being born premature because the only cure for preeclampsia is delivery. Women who have had preeclampsia are also at increased risk of cardiovascular and kidney disease later in life, including heart attack, stroke and high blood pressure. Studies show that women at high risk for preeclampsia, i.e., have had preeclampsia in a prior pregnancy, are carrying more than one fetus, have a history of high blood pressure, kidney disease or both, have certain medical problems such as diabetes, thrombophilia or lupus, have a modestly decreased risk of disease with daily intake of low-dose aspirin starting after 12 weeks of pregnancy.

Due to the limited data available on the topic of LDA in preeclamptic patients in the postpartum period, particularly as applicable to the American population, the investigator intends to start with a small pilot study involving the collection of information on 10 women not exposed to study intervention. This will allow for confirmation of the sample size based on the baseline FMD measurements 2 days after delivery.

Investigator will also explore a small sub-study to gather information regarding baseline FMD and biomarker values for healthy control postpartum patients, unaffected by preeclampsia and not on LDA during pregnancy or postpartum.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 2023
• Est. primary completion date: June 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Singleton or Multiple gestation

• Maternal age >= 18 years

• 20 0/7 weeks gestation or greater

• Severe Preeclampsia diagnosed prior to delivery

Exclusion Criteria:

• Aspirin use postpartum for other medical indication

• Lovenox, unfractionated heparin, or other anticoagulant use postpartum for an indication other than postoperative (in-house)

• Aspirin use within 7 days of planned initial FMD testing postpartum

• Hypersensitivity or allergy to Aspirin or other salicylates

• Hypersensitivity or allergy to nonsteroidal anti-inflammatory drugs (NSAIDs) - exception if taking LDA in pregnancy

• Nasal polyps

• Gastric or Duodenal ulcers, history of GI bleeding

• Severe hepatic dysfunction

• Bleeding disorders and diathesis

• Breastfeeding a newborn with low platelets (NAIT)

For sub-study patients, inclusion and exclusion criteria will be the same, with the exception of diagnosis of severe preeclampsia prior to delivery (exclusion criterion for healthy controls group).

Related Conditions & MeSH terms

• Pre-Eclampsia
• Preeclampsia Postpartum

Intervention

Drug:
• Aspirin tablet
Low dose aspirin, 81mg tablets, PO
• Placebo oral capsule
Placebo oral capsule, PO

Locations

Country	Name	City	State
United States	Columbia University Irving Medical Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Columbia University

Country where clinical trial is conducted

United States, 

References & Publications (2)

Costa AC, Reina-Couto M, Albino-Teixeira A, Sousa T. Aspirin and blood pressure: Effects when used alone or in combination with antihypertensive drugs. Rev Port Cardiol. 2017 Jul-Aug;36(7-8):551-567. doi: 10.1016/j.repc.2017.05.008. Epub 2017 Jul 3. English, Portuguese. — View Citation

The American College of Obstetricians and Gynecologists. Practice Advisory on Low-Dose Aspirin and Prevention of Preeclampsia: Updated Recommendations [Internet]. 2016. Available from: https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Practice-Advisory-Low-Dose-Aspirin-and-Prevention-of-Preeclampsia-Updated-Recommendations

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Flow-Mediated Dilation (FMD)	This is designed to measure if patients with preeclampsia with severe features diagnosed antepartum or intrapartum, will experience an increase in Flow-Mediated Dilation (FMD) - a measure of endothelial function - within 3 weeks after delivery when taking daily LDA in the postpartum period.	Up to 3 weeks postpartum
Secondary	Change in Systolic blood pressure	This is to measure if patients will experience a decrease in systolic blood pressure (SBP) within 3 weeks after delivery when taking daily LDA in the postpartum period.	Within 3 weeks postpartum
Secondary	Change in Diastolic blood pressure	This is to measure if patients will experience a decrease in diastolic blood pressure (DBP) within 3 weeks after delivery when taking daily LDA in the postpartum period.	Within 3 weeks postpartum
Secondary	Number of subjects with presentation of disease postpartum (symptoms, severe range BPs, lab abnormalities)	This is to measure if patients will experience decreased severity of disease when taking daily LDA in the postpartum period.	Up to 3 weeks postpartum
Secondary	Magnesium sulfate re-administration	This is to measure if patients will experience a decreased likelihood of receiving magnesium sulfate postpartum again when taking daily LDA in the postpartum period?	Up to 3 weeks postpartum
Secondary	Number of subjects with initiation of, increase in or addition of blood pressure medication	This is to measure if patients will experience a decreased rate in initiation of/ increase in/ addition of blood pressure medication postpartum when taking daily LDA in the postpartum period.	Up to 3 weeks postpartum
Secondary	Rate of hospital readmissions for postpartum preeclampsia	This is to measure if patients will experience a decreased rate of hospital readmissions for postpartum preeclampsia when taking daily LDA in the postpartum period.	Up to 3 weeks postpartum